Funder: Bill and Melinda Gates Foundation
Due Dates: April 1, 2026 (Letter of Inquiry deadline)
Funding Amounts: Up to $5,000,000 USD per project for up to 3 years; smaller, high-risk exploratory projects are encouraged.
Summary: Supports innovative, early-stage research to discover novel antibiotics targeting multidrug-resistant Gram-negative bacteria, with a focus on Klebsiella spp., through a collaborative consortium approach.
Key Information: Applicants must agree to consortium data sharing and collaboration requirements.